Business and Economics of Diabetes

Green MJ . The innovator will prevail in glucose monitoring. Med Device Technol. 2006; 17 (4): 32–3.

Cronquist Christensen Remler DM . Information and communications technology in chronic disease care: what are the implications for payment?. Med Care Res Rev. 2007; 64 (2): 123–47.

Palmer AJ Dinneen S Gavin JR 3rd Gray A Herman WH Karter AJ . Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin. 2006; 22 (5): 861–72.

Waugh N Scotland G McNamee P Gillett M Brennan Goyder E Williams R John A . Screening for type 2 diabetes: literature review and economic modeling. Health Technol Assess. 2007(17); 11: 1–125.

Straka RJ Mamdani M Damen J Kuntze CE Liu LZ Botteman MF Koren MJ . Economic impacts attributable to the early clinical benefit of atorvastatin therapy—a US managed care perspective. Curr Med Res Opin. 2007; 23 (7): 1517–29.

Lindgren P Lindström J Tuomilehto J Uusitupa M Peltonen M Jönsson B de Faire U Hellénius ML ; DPS Study Group. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care. 2007; 23 (2): 177–83.

Schmittdiel J Vijan S Fireman B Lafata JE Oestreicher N Selby JV . Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control. Med Care. 2007; 45 (4): 315–21.

Millett C Gray J Saxena S Netuveli G Majeed A . Impact of a pay-for-performance incentive on support for smoking cessation and on smoking prevalence among people with diabetes. CMAJ. 2007; 176 (12): 1705–10.